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The evidence and the rationale for the use of 
honey as a wound dressing
only seven randomised controlled trials (RCTs) conducted 
with honey and it was stated that “confidence in a conclusion 
that honey is a useful treatment for superficial wounds or 
burns is low”1. Although a more recent review2 included 
19 RCTs (with a total of 2,554 participants) and concluded 
that “honey may improve healing times in mild to moderate 
superficial and partial thickness burns compared with some 
conventional dressings”, it was stated that “the poor quality 
of most of the trial reports means the results should be 
interpreted with caution”, and that “there is insufficient 
evidence to guide clinical practice in other areas.”
The one trial excepted from this opinion that the quality of 
evidence was low was one which compared honey dressings 
with usual care on venous ulcers under compression3. 
This trial found that there was no significant difference 
between honey and other dressings used as an adjuvant 
to compression. However, it was an example of a common 
shortcoming of RCTs conducted on dressing wounds with 
honey, where the number of participants is not large enough 
to give a conclusive result, even in this instance where 
there were 368 participants. To be able to conclude with 
confidence that honey was no better than any other treatment 
would have required much larger numbers. It was originally 
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Abstract
Although there are now several brands and types of honey wound-care products available as registered medical devices, there is 
little promotional advertising of honey products for wound care. The misconception that there is no evidence to support the use 
of honey, which seems to be quite common, may be due to this lack of advertising, and to the systematic reviews that have been 
published on honey concluding that the evidence is of low quality and/or there is a need for more evidence. However, the same 
lack of high-quality evidence exists with all the other options that clinicians have for dressing wounds. This places practitioners 
in a quandary. When clinical evidence of the highest level is not available, then decisions on modes of treatment need to be 
based on whatever evidence there is available. This review outlines the 16 randomised controlled trials (RCTs) of honey in 
wound care published since Molan reviewed the previous 17 in 2006, which bring the total of participants in the trials up from 
1,965 to 3,556 and broadens the range of types of wounds on which trials with honey have been conducted. Another important 
factor influencing the choice by clinicians of which product to use on a wound is scientific rationale. This review covers the 
evidence and explanation of mode of action for various bioactivities in honey which aid wound healing: a very broad-spectrum 
antimicrobial activity that is effective on antibiotic-resistant strains; activation of autolytic debridement; anti-inflammatory 
activity; antioxidant activity; stimulation of growth of cells for tissue repair; and an osmotic action. The need for standardisation 
of these bioactivities is discussed.
Keywords: honey, review, clinical evidence, scientific rationale.
Introduction
With the move towards evidence-based practice, clinicians 
considering using honey will want to know what evidence 
there is to support it. There are now several brands and types 
of honey wound-care products available as registered medical 
devices (Table 1), but there is little promotional advertising of 
honey products for wound care. The misconception that there 
is no evidence to support the use of honey seems to be quite 
common and may be partly due to this lack of advertising. 
Also, anyone consulting the first of the two systematic reviews 
that have been published on the use of honey in wound care 
will get an impression of lack of evidence because it included 
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planned to conduct the trial on patients who had had no 
healing of ulcers after six weeks of compression. Such cases 
usually stay as non-healing ulcers for a long time, but a pilot 
trial had shown that honey gave healing of these within 6–12 
weeks4. However, to be able to get sufficient participants 
recruited there was no requirement that compression had 
been used, only that ulcers had been non-healing for six 
weeks. It can be expected that compression alone would 
give healing of venous ulcers in cases where there is no 
underlying complication, which would effectively decrease 
the number of participants in which honey would make a 
difference. Over the total number of participants there was 
5.9% more healing achieved at 12 weeks in the honey-treated 
group compared with those in the usual care group, the mean 
reduction from baseline ulcer area was 9.6% better and there 
were 23% fewer episodes of infection in the honey-treated 
group compared with those in the usual care group. With the 
number of participants in the trial it would have required a 
30% difference in the rate of healing to be achieved for the 
difference to be statistically significant. The results of the 
pilot trial indicated that a larger difference than that would 
be obtained, but with rapid healing in the uncomplicated 
Name of product Description of product Manufacturer
Algivon Alginate fibre dressing pad impregnated with manuka honey Advancis Medical
Activon Tulle Non-adherent gauze dressing impregnated with manuka honey Advancis Medical
Actilite Non-adherent gauze dressing impregnated with manuka honey and manuka oil Advancis Medical
Activon Tube Manuka honey in a tube Advancis Medical
HoneySoft Polyvinylacetate dressing impregnated with Chilean multifloral honey Taureon
Manuka Health Wound 
Dressing with Manuka Honey
Sheet of hydrogel sheet containing manuka honey Manuka Health NZ
Manuka Health Breast Pad 
with Manuka Honey
Sheet of hydrogel containing manuka honey Manuka Health NZ
Manuka Health Wound Gel Manuka honey with gelling agents, in a tube Manuka Health NZ
MANUKAhd Super-absorbent polyacrylic fibre dressing pad impregnated with manuka 
honey, coated with a dry-touch absorbent hydrocolloid
ManukaMed
MANUKAtex Non-adherent gauze dressing impregnated with manuka honey, coated with a 
dry-touch absorbent hydrocolloid 
ManukaMed
MANUKApli Manuka honey in a tube ManukaMed
Medihoney Honeycolloid Sheet of gelled manuka honey Dermasciences
Medihoney Calcium Alginate Alginate fibre dressing pad impregnated with manuka honey Dermasciences
Medihoney Manuka honey in a tube Dermasciences
MelMax Non-adherent wound dressing impregnated with a mixture of polyhydrated 
ionogens ointment and buckwheat honey
Dermagenics
MelDra Open-weave acetate fabric impregnated with buckwheat honey Dermagenics
L-Mesitran Soft Mixture of honey (not manuka) with lanolin, polyethylene glycol and vitamins C 
and E
Triticum
L-Mesitran Hydro Sheet of acrylic polymer hydrogel containing honey (not manuka) Triticum
L-Mesitran Net Open-weave polyester net impregnated with L-Mesitran Hydro Triticum
L-Mesitran Ointment Mixture of honey (not manuka), lanolin, cod liver oil, sunflower oil, calendula, 
aloe vera, zinc oxide and vitamins C and E
Triticum
Table 1. Registered sterilised wound care products incorporating honey that are on sale.
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ulcers (the more common ones) occurring anyway as a result 
of compression being used, the average difference was lower. 
To get statistical significance with a smaller difference would 
have required a larger sample size, for example, for a 10% 
difference 1,030 participants would have been required.
Other reviews of the published evidence for honey have also 
come to the conclusion that the evidence is of low quality 
and/or there is a need for more evidence5-8. However, the 
same lack of high-quality evidence exists with all the other 
options that clinicians have for dressing wounds. It is likely 
that people are less aware of this because of the very large 
volume of advertising of wound-care products: this author 
frequently hears of clinicians who will not consider using 
honey on wounds because of lack of evidence for it, implying 
that they think that there is better evidence for the products 
that they choose to use instead. Systematic reviews of the 
evidence for the products usually used to treat common 
types of wounds have shown that this is not the case. (The 
conclusions from these reviews are shown in Table 2.)
Leaper9 has discussed the inadequacy of evidence for 
wound dressings in general and the difficulties faced in ever 
obtaining high-quality evidence. He points out the quandary 
in which this places the inexperienced practitioner and 
questions where that practitioner can turn for help when 
making decisions. When clinical evidence of the highest 
level is not available, then decisions on modes of treatment 
of cases need to be based on whatever evidence there is 
available. There is a hierarchy of evidence. According to 
Campbell10, double-blind RCTs give the strongest evidence, 
with the next strongest evidence coming from single-blind 
RCTs, then from open RCTs, next from non-randomised 
studies, next from controlled case studies, then from case 
studies. It is almost impossible to conduct double-blind 
trials with honey on conscious patients because they will be 
able to detect the characteristic aroma of honey. Campbell 
does not mention animal studies, but the many studies that 
have been conducted using honey dressings on animals 
have been useful in this respect because they eliminate any 
Treatment Conclusions Ref. no.
Advanced dressings on pressure ulcers Their generalised use for this treatment is not supported by high-
quality evidence.
93
Dressings and topical agents for surgical wounds 
healing by secondary intention
Only small, poor-quality trials exist, rendering the evidence 
insufficient.
94
The various dressings in use to prevent infection 
in surgical wounds healing by primary intention
No evidence was found that any of the dressings were better than 
using no dressing at all.
95
Hydrogel dressings to promote the healing of 
diabetic foot ulcers
Uncertain findings of superiority over basic wound contact dressings 
have been reported and no RCTs comparing hydrogel with other 
advanced dressing types were found.
96
The many kinds of dressings used on venous 
ulcers
No evidence was found that any affected the rate of healing of the 
ulcers.
97
The many dressings available to treat superficial 
and partial-thickness burns
None had strong evidence to support their use and there was no 
evidence to support the use of silver sulfadiazine.
98
Silver dressings for treatment of infected or 
contaminated chronic wounds
There is insufficient evidence to recommend the use of these or 
silver-containing topical agents.
99
Silver-containing dressings and topical agents 
for the treatment of diabetic foot ulcers
No randomised or controlled trials were found for inclusion in a 
systematic review of their use, despite their widespread use for this 
treatment.
100
Silver-containing dressings and topical agents 
for the prevention of wound infection
No significant difference was found between these and the nine non-
silver dressings they were compared with. There were significantly 
fewer infections with silver sulfadiazine/hydrocolloid in one trial and 
significantly more infections in one trial with silver sulfadiazine. Only 
one trial showed a significant reduction in healing time with a silver-
containing dressing (hydrofibre, on diabetic foot ulcers).
101
Table 2. Conclusions from systematic reviews of wound treatments.
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placebo effect, which is likely to be large because there is so 
much public awareness of honey being used successfully11. 
A review published by Molan in 200612 of the evidence for 
the effectiveness of honey included 16 trials on wounds on 
experimental animals. There have been a further 11 such 
studies published13-23 since the ones covered in that review.
The evidence supporting the use of honey 
in wound care
The review by Molan12 also included a lot of other evidence 
that got excluded from the other reviews that have been 
published. In total in this review, positive findings for honey 
in wound care were found to have been reported in all of the 
17 RCTs involving a total of 1,965 participants, and in the 
five clinical trials of other forms involving 97 participants 
treated with honey. The benefit of honey in assisting wound 
healing was also found to have been demonstrated in four 
case studies where there were multiple wounds, allowing 
comparison of honey with other treatment. The review 
also summarised the details of 10 reports of studies of case 
series (totalling 276 cases). Honey gave good results in all 
but 14 of these cases. These case series were mostly chronic 
wounds. The clinical trials were on superficial and partial-
thickness burns, infected surgical wounds, chronic leg ulcers, 
pressure ulcers, pyomyositis abscesses, donor sites from 
split-thickness skin grafts, Fournier’s gangrene (a form of 
necrotising fasciitis) and exit sites for central vein catheters.
An editorial commentary on this review24 noted the importance 
of considering evidence lower down in the hierarchy and 
stated the opinion, “Every potential remedy that does no 
harm needs to be examined for its use and availability for 
the good of all.” The evidence for honey doing no harm is to 
be seen in the absence of any adverse effects being reported 
in all of the trials covered in the above-mentioned review 
and in all the published trials and the many case studies 
cited below in the present article. It is frequently reported by 
patients that honey causes a stinging pain, but this is when 
wounds are inflamed and it has been found to be due to the 
acidity of honey4. The nociceptor nerve endings which detect 
acidity are sensitised by inflammation, which explains the 
clinical observation that the sensitivity to honey decreases in 
a few days if sufficient honey is kept on the wound bed to 
allow the anti-inflammatory activity of honey to suppress the 
inflammation. In a large RCT of honey dressings on venous 
ulcers3 29 more participants in the honey group found the 
dressings more painful than did those in the regular care 
group, but only four of the 187 treated with honey found the 
pain sufficient to withdraw from the trial.
As well as this RCT the results of a further 16 clinical trials of 
honey in wound care have been published in the five years 
since the review by Molan was published in 2006. The details 
of these are summarised in Table 3. These broaden the range 
of types of wounds on which trials with honey have been 
conducted and together bring the total of participants in RCTs 
on honey up from 1,965 to 3,556.
Rationale	for	use	of	honey	in	wound	care
Another important factor influencing the choice by clinicians 
of which product to use on a wound is scientific rationale. 
Despite the modern mantra of ‘evidence-based medicine’, 
this factor is as important today as it was in days gone by. 
In a paper on acupuncture published by John Renton in the 
Edinburgh Medical and Surgical Journal nearly two centuries 
ago25 he wrote: 
And when, moreover, no satisfactory explanation can be 
afforded of the modus operandi of the reagent, professional 
persons, unhappily for the interests of medical science, are too 
apt to reason upon the authenticity of the facts averred, instead 
of adopting the more simple and direct method of determining 
their value by subjecting them to the test of farther experience. 
To put this in modern language, he was saying that if 
medical professionals do not know how a product works 
they will dispute the evidence rather than try the product. 
The importance of rationale for products in clinical decisions 
is well illustrated by the huge size of the market that was 
built up for silver dressings based on advertising that silver 
was released and killed bacteria, when there was no high-
quality clinical evidence for it doing so in wound infections. 
The rationale for the action of honey in bringing about 
clearance of infection in wounds and accelerating healing 
is well established but not well known, having not been 
advertised. Even less well known about honey by wound 
care practitioners are its other bioactivities which are also 
important in promoting wound healing: activation of autolytic 
debridement, anti-inflammatory activity, antioxidant activity, 
stimulation of growth of cells for tissue repair, and an 
osmotic action. There is good evidence from clinical studies, 
laboratory studies and studies with animal models for honey 
having these bioactivities. These are summarised in Table 4, 
and are discussed in more detail in the following sections.
Antibacterial activity of honey
The evidence for the antibacterial properties of honey relevant 
to wound care was reviewed by Molan in 200926. The number 
of reports published on the antibacterial activity of honey 
is very large, but honey varies greatly in its antibacterial 
potency27 so the review by Molan26 focused on studies which 
used large numbers of different samples of honey to get 
representative results, or used honeys with their antibacterial 
activity standardised against phenol as a reference antiseptic. 
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In these studies, the minimum inhibitory concentration of 
honey has been found for a broad range of bacterial species 
which infect wounds. This level is generally less than 10%, a 
concentration of honey that is usually well below that which 
would be present on a wound bed under a honey dressing. 
Fungal species are generally less susceptible to honey, with 
the minimum inhibitory concentration of honey being in the 
range of 10%–50%26. Honey has been found to have a very 
broad spectrum of antibacterial activity, it being inhibitory 
to Gram-positive and Gram-negative species, and to both 
aerobes and anaerobes26. Of particular interest to wound-care 
practitioners is its effectiveness against antibiotic-resistant 
strains of bacteria such as Pseudomonads, MRSA, coagulase-
negative Staphylococci, VRE, Acinetobacter baumanii and 
Stenotrophomonas maltophilia. Also of clinical interest is the 
finding in long-term “resistance training” experiments with 
four wound-infecting species of bacteria that no permanent 
decrease in susceptibility to honey could be created and no 
honey-resistant mutants could be detected28. It was concluded 
by the authors that the risk of bacteria acquiring resistance 
to honey is low as long as high concentrations of honey are 
maintained clinically. The review by Molan26 also outlined 
the evidence from seven clinical trials, three case series 
studies and one case report for the effectiveness of honey 
dressings clearing infection in wounds. In many of the cases 
honey worked where other antibacterial therapy had failed. 
A possible explanation for this may be because honey has 
been found to be effective against bacteria in biofilms29-31, a 
situation where antibiotics and silver wound dressings have 
been found to be ineffective32.
Debriding action of honey
The debriding action of honey may also be useful clinically 
in combatting bacteria in biofilms in chronic wounds. A 
strategy (called biofilm-based wound care) has been designed 
to tackle the problem, of which a major component is 
aggressive debridement33. The evidence for the effectiveness 
of honey as a debriding agent was reviewed by Molan in 
200934. This evidence included an RCT with 108 participants35, 
which demonstrated better debriding with honey than with 
hydrogel, the mean wound area covered in slough after four 
weeks being reduced to 29% with honey, compared with 43% 
with hydrogel; however, this difference was not statistically 
significant (p=0.065). The review also outlined other trials 
which have shown that honey is a good alternative to surgical 
debridement for the treatment of necrotising fasciitis in the 
genital region. Furthermore, it outlined seven case series and 
10 single case studies in which the effectiveness of honey 
in debriding wounds was reported. In an RCT comparing 
honey with silver sulfadiazine for the treatment of burns, 
honey was found to prevent the formation of eschar, whereas 
it was formed in the cases treated with silver sulfadiazine36. 
Similarly, in a trial on adjacent experimental wounds on 
rabbits the wounds were kept clean with honey-soaked gauze 
but the ones treated with saline-soaked gauze formed thick 
dense scabs13.
A possible explanation for the mechanism by which honey 
brings about debridement of wounds has recently been found. 
Working with cultures of inflamed macrophages it was found 
that honey increased the activity of the enzyme plasmin in the 
culture medium (Harcourt and Molan: paper submitted for 
publication). Plasmin efficiently digests fibrin, which is what 
attaches slough to the wound surface, but does not digest the 
collagen matrix which is needed for tissue repair. The study 
found that the plasmin activity is increased by way of honey 
inhibiting the production of plasminogen activator inhibitor 
(PAI) by the macrophages, which otherwise would block 
enzymically inactive plasminogen from being converted to 
active plasmin by plasmin activator. Inflammation increases 
production of PAI37, hence the decrease in production of PAI 
brought about by honey is to be expected because it is well-
established that honey has anti-inflammatory activity.
Anti-inflammatory activity of honey
The large body of evidence for honey having anti-
inflammatory activity comes from many sources. Clinically 
there have been numerous observations reported of honey 
reducing oedema and exudate, minimising scarring and 
having a soothing effect when applied to inflamed wounds 
and burns36,38-45. Direct evidence of an anti-inflammatory 
activity in clinical settings has been obtained biochemically 
in the form of decreased levels of malondialdehyde46 and 
lipid peroxide47, and histologically in observation of reduced 
numbers of inflammatory cells present in biopsy samples36 in 
clinical trials where burns were dressed with honey. Evidence 
that honey has a direct anti-inflammatory activity, and that 
it is not a secondary effect from the antibacterial activity of 
honey removing bacteria which are causing inflammation, 
is seen in the many reports of anti-inflammatory activity 
being observed in experimental wounds and burns in animal 
models, where there were few or no bacteria present in 
these aseptically produced wounds48. The anti-inflammatory 
activity of honey has also been shown in various clinical trials 
where it decreased the severity of mucositis in radiotherapy 
of the head and neck region49-52, decreased symptoms of 
dyspepsia53 and decreased the number of bleeding sites 
on gums in a trial of its use to treat gingivitis54. It was also 
found to be effective in relief of various ophthalmological 
inflammatory conditions55, and in decreasing pain in non-
healing leg ulcers56 and after surgical removal of children’s 
tonsils57. The results obtained in animal experiments have 
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also demonstrated the anti-inflammatory activity of honey: 
chemically induced colitis in rats was decreased58-61 and 
prior dosage of honey to rats prevented gastritis being 
caused by subsequent dosage of ethanol62-64. Injection of 500 
µl of 50% honey into rat paws one hour prior to injection of 
lipopolysaccharide gave less swelling, reduced sensitivity to 
pain, and a lower level of nitric oxide and prostaglandin E265.
There are possibly several mechanisms of action by which 
honey gives an anti-inflammatory effect. It has been reported 
that honey inhibits complement that has been activated by the 
classical pathway, some honeys giving a 50% inhibition at a 
concentration of less than 1%66. Inhibition of the production of 
nitric oxide by macrophages by solvent extracts of honey has 
also been reported, but to achieve 75% inhibition of production 
the concentration of extract required was equivalent to honey 
at a concentration of more than 50%67. It has also been 
proposed that the anti-inflammatory action is also due to 
inactivation of reactive oxygen species (ROS) produced in 
the ‘respiratory burst’ of phagocytes, and to inhibition of 
their production66,68. Inhibition by honey of production of 
ROS by zymosan-activated neutrophils66, zymosan-activated 
neutrophils, monocytes and macrophages69, thrombin-
activated neutrophils70 and zymosan-activated monocytes 
primed with lipopolysaccharide71 has been reported, there 
being inhibition of 50% or more obtained with a concentration 
of 1% or less with some honeys. Although a stimulation of 
the ‘respiratory burst’ of neutrophils has been reported to 
be brought about by honey, this stimulation was maximal 
at 0.1% honey, and at 0.8% honey (the highest concentration 
tested) there was 46% inhibition of the ‘respiratory burst’72. 
The possibility that the decrease in production of ROS 
reported was due to the antioxidant components of honey 
scavenging the ROS and preventing them reacting with the 
reagents used to measure them, rather than honey directly 
inhibiting the ‘respiratory burst’ has been investigated, and 
this has been discounted by the finding that honey has an 
inhibitory action on the process of phagocytosis which is 
what activates the ‘respiratory burst’ (Bean, Cursons and 
Molan: paper submitted for publication).
Antioxidant activity of honey
The antioxidant activity of honey probably also contributes 
to its anti-inflammatory properties because ROS act as 
messengers to give feedback amplification of the inflammatory 
response73, and this process can be blocked by phenolic 
antioxidants74. It has been demonstrated that application 
of antioxidants to wounds decreases inflammation75,76, and 
the main mechanism of action of honey in improving the 
healing of burns has been found to be through its antioxidant 
activity77. Manuka honey, the type of honey most widely 
used in registered wound-care products, contains a very high 
level of phenolics78. One of these compounds present at a 
high level, methyl syringate, has been identified as a potent 
superoxide scavenger79 and thus can be expected to remove 
one of the major ROS messengers amplifying inflammation.
Although there has been little reference to anti-inflammatory 
activity in promotion of wound-care products because anti-
inflammatory pharmaceuticals are not compatible with 
wound healing (non-steroidal anti-inflammatory drugs are 
cytotoxic, and corticosteroids inhibit the growth of epithelial 
tissue), inflammation is a major factor in chronic wounds 
remaining non-healing80. Also, by giving rise to ROS, which 
over-activate fibroblasts, inflammation causes fibrosis81 which 
in cutaneous wounds gives hypertrophic scars. This would 
explain why when honey, which has an anti-inflammatory 
activity, has been used in clinical trials to treat burns its 
usage results in less scarring44,82. The ROS produced by 
phagocytes in inflamed tissue also activate proteases which 
are normally inactive83-85 and the active forms of these digest 
the extracellular matrix and cell growth factors which are 
essential for tissue repair86. The anti-inflammatory action of 
honey suppressing this activation would explain why in a 
clinical trial of use of honey to treat superficial burns none 
of the burns became full-thickness with honey whilst four 
did that were treated with silver sulfadiazine36. Another 
benefit of the anti-inflammatory action of honey is that 
it decreases oedema, thus decreasing the pressure on the 
microvasculature of wound tissue that otherwise restricts the 
availability of oxygen and nutrients required for growth of 
tissue for wound repair.
Increasing the rate of healing
The acidity of honey also helps provide oxygen to regenerating 
tissue, as it decreases the pH of the wound bed and thus 
makes more oxygen available from haemoglobin in the 
blood. A clinical trial to find the effect of honey dressings on 
the surface pH of chronic wounds demonstrated it to cause 
a significant p<0.001) decrease in pH, a reduction in pH of 
0.1 being significantly (p<0.001) associated with a decrease 
in wound size of 8.1%87. An additional action in speeding the 
growth of repair tissues is the stimulatory action of honey 
on growth of cells. Honey at a concentration of 1% has been 
found to significantly (p<0.001) stimulate the release of the 
cytokines TNF-α, IL-1β and IL-6 from monocytes when 
compared with untreated cells, something known to play an 
important role in healing and tissue repair88. Keratinocytes, 
another type of cell involved in wound healing, have been 
found to have transcription of the genes for TNF-α, IL-1β 
and TGF-β up-regulated by honey a concentration of 1%89. 
Honey has also been demonstrated to stimulate angiogenesis 
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in vitro in a rat aortic ring assay, maximally at around a 0.2% 
concentration of honey90. The osmotic action, resulting from 
honey consisting of approximately 80% sugars, also helps 
with increasing the availability of oxygen and nutrients for 
growth of repair tissues, in the same way as VAC therapy 
does. Another advantage of the osmotic action is that it 
creates a liquid layer between the dressing and the wound 
bed, thus not only giving painless removal of dressings but 
also avoiding damage to newly grown tissue, which, if it 
adhered to the dressing, could be torn off the wound during 
removal of dressings. The sugar content of this liquid layer 
makes it hypertonic and this along with decreased protease 
activity resulting from suppression of inflammation accounts 
for why maceration is not seen when wounds are dressed 
with honey.
Challenges posed by variation in 
composition of honey
There is a major challenge faced both in providing honey 
wound dressings with the best functionality and in obtaining 
clinical evidence for the use of honey as a wound dressing. 
This challenge is to take into account the large degree of 
variation in potency of each of the bioactivities of honey 
relevant to achieving optimal wound healing. It is a challenge 
faced with all natural products used medically. Unless the 
component(s) responsible for any therapeutic action(s) are 
known and the level of these components are standardised 
then the results obtained clinically may vary, and any results 
obtained from use of the products are applicable only to the 
particular batch used and cannot be attributed to the product 
in general. What also needs to be considered is that more 
than one bioactivity may be involved in achieving the clinical 
results obtained, so there needs to be careful choice of wound 
types on which clinical trials are conducted so that only the 
bioactivities that have been standardised in the honey used 
are likely to be involved in achieving the outcomes recorded. 
As an example of these points, the RCT that was conducted 
to compare manuka honey with hydrogel for desloughing 
efficacy in venous ulcers35 gave results that demonstrated 
only that the particular batch of honey used had the relative 
efficacy found. A different batch of honey, even of the same 
Antibacterial activity:
•	 Very	broad	spectrum	of	activity	(antifungal	as	well) 
•	 Effective	against	antibiotic-resistant	species 
•	 Effective	against	bacteria	in	biofilms 
•	 The	minimum	inhibitory	concentration	with	bacteria	is	generally	less	than	10%	honey 
•	 Development	of	resistance	to	honey	is	unlikely
Debriding action:
•	 Acts	to	activate	plasminogen	which	lyses	fibrin	attaching	slough 
•	 Prevents	formation	of	eschar	and	scabs
Anti-inflammatory activity:
•	 Many	reports	of	clinical	observation	of	decrease	in	symptoms	of	inflammation 
•	 Biochemical	and	histological	studies	have	demonstrated	decreased	inflammation 
•	 The	action	is	direct,	not	secondary	to	clearing	infection	causing	inflammation 
•	 Demonstrated	in	many	studies	on	inflammation	in	sites	other	than	wounds 
•	 Acts	to	inhibit	phagocytosis,	the	start	of	the	inflammatory	response
Antioxidant activity of honey:
•	 Contains	plant	phenolics	from	the	nectar	source 
•	 Scavenges	reactive	oxygen	species	which	act	as	messengers	between	cells	to	increase	the	inflammatory	process	and	cause	 
 hypertrophic scarring 
•	 Decreases	oxidative	activation	of	proteases	which	destroy	the	matrix	and	growth	factors
Increasing the rate of healing:
•	 Stimulates	leukocytes	to	release	cytokines	and	growth	factors	that	activate	tissue	repair 
•	 Acidity	of	honey	makes	more	oxygen	available	from	the	circulation	for	tissue	repair 
•	 Osmotic	action	causes	outflow	of	lymph	like	in	VAC	therapy
Table 4. Summary of the actions of honey promoting wound healing.
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product from the same manufacturer, may have shown less 
(or greater) efficacy because only the antibacterial activity had 
been standardised in the product yet it would be expected 
that the unstandardised components of the honey responsible 
for increasing plasmin activity and suppressing inflammation 
would also be involved in achieving desloughing.
The antibacterial activity of honey can vary up to 100-fold in 
potency27. There is also the issue of whether the antibacterial 
activity is due to hydrogen peroxide (which could be to a large 
degree inactivated by catalase activity in the wound bed) or 
to non-peroxide factors as occur in some (but not all) honey 
described as manuka honey91. In research work investigating 
the mechanism of action of the debriding properties of honey, 
the increase in plasmin activity stimulated by samples of 
different honeys (tested at a concentration of 1%) was found 
to range from 21% to 103% (Harcourt and Molan: paper in 
preparation). In research work investigating the mechanism 
of action of the anti-inflammatory activity of honey (Bean, 
Cursons and Molan: paper submitted for publication) the 
degree of suppression of phagocytosis by samples of different 
honeys (tested at a concentration of 0.25%) was found to 
range from zero to 50% inhibition. Twofold70, threefold69 and 
fourfold66 differences between different samples of honey 
in inhibition of the formation of ROS by leukocytes have 
been reported. Also, a fourfold difference between different 
samples of honey in inhibition of complement has been 
reported66. Differences between different samples of honey 
in the degree of stimulation of production of cytokines by 
leukocytes71,88 and degree of stimulation of angiogenesis90 
have also been reported.
Some, maybe all, of the registered honey wound-care 
products on sale have the antibacterial activity standardised, 
thus there can be confidence that results from trials where 
clearance of infection has been reported with these products 
are likely to be achieved in clinical practice. The level of the 
antibacterial activity in the registered products is usually not 
stated because this could be construed as a therapeutic claim, 
something not allowed for products in the ‘medical device’ 
class in which they are registered. The public can purchase 
honey on which the level of antibacterial activity is stated; 
however, it is very much a case of caveat emptor because 
many marketers do not make clear whether the activity that 
is rated is non-peroxide (that is, not inactivated by catalase 
in wounds) or is due to hydrogen peroxide which could be 
inactivated. It is the author’s view that it needs to be taken 
into account in clinical practice that the registered honey 
wound dressings on sale also differ from manufacturer to 
manufacturer in which type of antibacterial activity the honey 
has. Although there has been no clinical trial to compare the 
efficacy of the two types of activity there is a rationale to 
support choosing honey with non-peroxide activity where 
the best antibacterial activity is wanted.
In vitro assays for the ability of samples of honey to stimulate 
production of cytokines and growth factors which stimulate 
tissue repair have already been published. These could be used 
to ensure that honey for wound-care products is standardised 
for this therapeutic activity. With research from the author’s 
laboratory expected to be published soon describing in vitro 
assays for bioactivities involved in debriding of wounds and 
decreasing inflammation, it should be possible to have honey 
products standardised for these actions as well. Research 
in the author’s laboratory is near completion developing 
an in vitro assay for the efficacy of antioxidants inside cells, 
which is be much more relevant to wound care than the 
standard antioxidant assays used by the food industry. (Many 
antioxidants do not cross cell membranes efficiently.)
Concluding comments
Honey may be considered by some clinicians to be an 
“alternative medicine” or a “complementary medicine”, 
and its reputation as a cure-all in the health food market 
may well cause clinicians to not give it due consideration 
for use in wound care. But honey is no more “alternative” 
or “complementary” than tulle gras, sutures, elasticated 
compression bandages and silver which, like honey, were 
commonly used in wound care about a century ago92. 
Like silver did, honey went out of common usage when 
antibiotics came into use in the early 1940s, and like silver 
it is coming back into use now that the problem of bacterial 
resistance to antibiotics is becoming widespread. The clinical 
and scientific evidence from modern research outlined in 
this review should make it clear that, at least in its use in 
wound care, honey should be considered alongside modern 
pharmaceutical products with regard to its effectiveness 
and therapeutic actions. However, other than in its physical 
properties and in its antibacterial activity in brands of honey 
wound-care products where this is standardised, there is an 
inherent weakness with respect to the variation in the level 
of bioactivities that occurs in all natural products used in 
medicine. It is next a matter of persuading manufacturers of 
honey products for wound care to standardise their products 
for all of the therapeutic activities that honey has, so that 
clinicians can use honey products with the confidence of 
knowing that they should have the same efficacy as when 
used on previous cases.
It is only with all of the relevant therapeutic activities 
standardised can conclusive clinical trials be conducted. 
At present there is insufficient high-quality evidence from 
trials of conventional treatments to establish, for each type 
of wound, what is the best treatment against which honey 
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should be compared in clinical trials, so in the meantime any 
trials should have as the control what is generally accepted as 
the standard treatment in modern wound-care practice. The 
control treatment, and the type of honey dressing used, will 
need to be selected to suit the type of wound being studied. 
Pilot trials may be needed to find the best type of honey 
dressing to use, rather than having the choice directed by 
sponsorship by manufacturers. In order to get statistically 
significant conclusions on which of the two treatments 
compared (honey or standard best practice) gives the best 
results the number of patients recruited into trials needs to be 
large enough to allow for the degree of variation that occurs 
between individuals in rate of healing for each type of wound, 
and for the expected (from pilot trials) degree of difference in 
effectiveness between honey and standard treatment.
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